106 related articles for article (PubMed ID: 32803782)
1. MicroRNA-191 modulates cisplatin-induced DNA damage response by targeting RCC2.
Xu X; Zhou X; Zhang J; Li H; Cao Y; Tan X; Zhu X; Yang J
FASEB J; 2020 Oct; 34(10):13573-13585. PubMed ID: 32803782
[TBL] [Abstract][Full Text] [Related]
2. RCC2, a regulator of the RalA signaling pathway, is identified as a novel therapeutic target in cisplatin-resistant ovarian cancer.
Gong S; Chen Y; Meng F; Zhang Y; Wu H; Li C; Zhang G
FASEB J; 2019 Apr; 33(4):5350-5365. PubMed ID: 30768358
[TBL] [Abstract][Full Text] [Related]
3. MiR-29c is downregulated in gastric carcinomas and regulates cell proliferation by targeting RCC2.
Matsuo M; Nakada C; Tsukamoto Y; Noguchi T; Uchida T; Hijiya N; Matsuura K; Moriyama M
Mol Cancer; 2013 Feb; 12():15. PubMed ID: 23442884
[TBL] [Abstract][Full Text] [Related]
4. RCC2 contributes to tumor invasion and chemoresistance to cisplatin in hepatocellular carcinoma.
Chen Q; Jiang P; Jia B; Liu Y; Zhang Z
Hum Cell; 2020 Jul; 33(3):709-720. PubMed ID: 32239438
[TBL] [Abstract][Full Text] [Related]
5. DNA damage responsive miR-33b-3p promoted lung cancer cells survival and cisplatin resistance by targeting p21
Xu S; Huang H; Chen YN; Deng YT; Zhang B; Xiong XD; Yuan Y; Zhu Y; Huang H; Xie L; Liu X
Cell Cycle; 2016 Nov; 15(21):2920-2930. PubMed ID: 27559850
[TBL] [Abstract][Full Text] [Related]
6. miR-638 suppresses DNA damage repair by targeting SMC1A expression in terminally differentiated cells.
He M; Lin Y; Tang Y; Liu Y; Zhou W; Li C; Sun G; Guo M
Aging (Albany NY); 2016 Jul; 8(7):1442-56. PubMed ID: 27405111
[TBL] [Abstract][Full Text] [Related]
7. MiR-155 inhibits the sensitivity of lung cancer cells to cisplatin via negative regulation of Apaf-1 expression.
Zang YS; Zhong YF; Fang Z; Li B; An J
Cancer Gene Ther; 2012 Nov; 19(11):773-8. PubMed ID: 22996741
[TBL] [Abstract][Full Text] [Related]
8. Epigenetically altered miR-1247 functions as a tumor suppressor in pancreatic cancer.
Yi JM; Kang EJ; Kwon HM; Bae JH; Kang K; Ahuja N; Yang K
Oncotarget; 2017 Apr; 8(16):26600-26612. PubMed ID: 28460450
[TBL] [Abstract][Full Text] [Related]
9. MiR-509-3-5p causes aberrant mitosis and anti-proliferative effect by suppression of PLK1 in human lung cancer A549 cells.
Wang XH; Lu Y; Liang JJ; Cao JX; Jin YQ; An GS; Ni JH; Jia HT; Li SY
Biochem Biophys Res Commun; 2016 Sep; 478(2):676-82. PubMed ID: 27498003
[TBL] [Abstract][Full Text] [Related]
10. Targeting miR-21-3p inhibits proliferation and invasion of ovarian cancer cells.
Báez-Vega PM; Echevarría Vargas IM; Valiyeva F; Encarnación-Rosado J; Roman A; Flores J; Marcos-Martínez MJ; Vivas-Mejía PE
Oncotarget; 2016 Jun; 7(24):36321-36337. PubMed ID: 27166999
[TBL] [Abstract][Full Text] [Related]
11. RCC2 over-expression in tumor cells alters apoptosis and drug sensitivity by regulating Rac1 activation.
Wu N; Ren D; Li S; Ma W; Hu S; Jin Y; Xiao S
BMC Cancer; 2018 Jan; 18(1):67. PubMed ID: 29321004
[TBL] [Abstract][Full Text] [Related]
12. Paraspeckle protein 1 (PSPC1) is involved in the cisplatin induced DNA damage response--role in G1/S checkpoint.
Gao X; Kong L; Lu X; Zhang G; Chi L; Jiang Y; Wu Y; Yan C; Duerksen-Hughes P; Zhu X; Yang J
PLoS One; 2014; 9(5):e97174. PubMed ID: 24819514
[TBL] [Abstract][Full Text] [Related]
13. miR-181a and miR-630 regulate cisplatin-induced cancer cell death.
Galluzzi L; Morselli E; Vitale I; Kepp O; Senovilla L; Criollo A; Servant N; Paccard C; Hupé P; Robert T; Ripoche H; Lazar V; Harel-Bellan A; Dessen P; Barillot E; Kroemer G
Cancer Res; 2010 Mar; 70(5):1793-803. PubMed ID: 20145152
[TBL] [Abstract][Full Text] [Related]
14. The effect of combined miR-200c replacement and cisplatin on apoptosis induction and inhibition of gastric cancer cell line migration.
Ghasabi M; Majidi J; Mansoori B; Mohammadi A; Shomali N; Shirafkan N; Baghbani E; Kazemi T; Baradaran B
J Cell Physiol; 2019 Dec; 234(12):22581-22592. PubMed ID: 31111481
[TBL] [Abstract][Full Text] [Related]
15. miR-144 reverses cisplatin resistance in cervical cancer via targeting LHX2.
Shi F; Su J; Liu Z; Wang J; Wang T
J Cell Biochem; 2019 Sep; 120(9):15018-15026. PubMed ID: 31017720
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-138 modulates DNA damage response by repressing histone H2AX expression.
Wang Y; Huang JW; Li M; Cavenee WK; Mitchell PS; Zhou X; Tewari M; Furnari FB; Taniguchi T
Mol Cancer Res; 2011 Aug; 9(8):1100-11. PubMed ID: 21693595
[TBL] [Abstract][Full Text] [Related]
17. Suppression of long noncoding RNA NCK1-AS1 increases chemosensitivity to cisplatin in cervical cancer.
Zhang WY; Liu YJ; He Y; Chen P
J Cell Physiol; 2019 Apr; 234(4):4302-4313. PubMed ID: 30221354
[TBL] [Abstract][Full Text] [Related]
18. Cisplatin resistance in non-small cell lung cancer cells is associated with an abrogation of cisplatin-induced G2/M cell cycle arrest.
Sarin N; Engel F; Kalayda GV; Mannewitz M; Cinatl J; Rothweiler F; Michaelis M; Saafan H; Ritter CA; Jaehde U; Frötschl R
PLoS One; 2017; 12(7):e0181081. PubMed ID: 28746345
[TBL] [Abstract][Full Text] [Related]
19. Effects of microRNA-1271 on ovarian cancer via inhibition of epithelial-mesenchymal transition and cisplatin resistance.
Chen Y; Wang L; Zhou J
J Obstet Gynaecol Res; 2019 Nov; 45(11):2243-2254. PubMed ID: 31411791
[TBL] [Abstract][Full Text] [Related]
20. RCC2 promotes proliferation and radio-resistance in glioblastoma via activating transcription of DNMT1.
Yu H; Zhang S; Ibrahim AN; Wang J; Deng Z; Wang M
Biochem Biophys Res Commun; 2019 Aug; 516(3):999-1006. PubMed ID: 31277942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
